Presentation (CTI)

OBJECTIVES: As rare disease pipelines mature with new product launches and competition increases over time, payers are adopting more sophisticated utilization management strategies. This research aims to assess product- and market-level factors associated with payer management/control in rare diseases, and to explore development of a model to estimate the likelihood of payer management for a given rare disease product.
METHODS: A secondary research approach evaluated payer coverage criteria for selected branded rare disease therapies across a sample of commercial payers and rare diseases. Rare diseases were selected on the basis of strong competition (multiple mechanisms and routes of action) at significant prices. A broad set of independent variables was examined across pricing, competitive landscape, and clinical profile domains. Analytical methods included single-variable regressions, multivariate regression modeling, and Random Forest machine learning to identify directional associations and interaction effects.
RESULTS: Across analytic methods, competitive and clinical factors emerged as consistent directional drivers of payer control, though relationships varied by indication context. Measures related to prevalence, years on market, route of administration, and adherence showed notable associations with payer management in single-variable analyses. Multivariate modeling suggested that launch competition and indication-specific characteristics may contribute meaningfully when considered jointly, though overall explanatory power remained limited. Machine learning analyses highlighted the importance of competitive landscape variables, although data skew and overfitting were significant challenges.
CONCLUSIONS: Payer control in rare disease appears to be influenced by a complex interplay of competitive, clinical, and market factors rather than any single determinant. While quantitative modeling can directionally inform risk assessment, results reinforce the need to complement analytics-based approaches with qualitative payer insights.